Multicenter retrospective cohort study of long-term oncological outcomes of breast-conserving treatment in patients with BRCA1/2 pathogenic variants

Dr. CHihwan David Cha

A retrospective study at 13 centers in South Korea investigated long-term outcomes after breast-conserving treatment (BCT; 66.2% of patients) or mastectomy (33.8%) for breast cancer in patients with BRCA1/2 pathogenic variants. After propensity score matching, there were no significant differences in long-term oncological outcomes between the two groups. The authors conclude that BCT can be considered a viable treatment option for patients with breast cancer with BRCA1 or BRCA2 pathogenic variants.